EGFR and neoplasm: Directing treatment against a dominant clonal neoantigen can additionally lead to tumor resistance via neoantigen loss, as illustrated in a case of EGFR-mutated NSCLC that lost the EGFR driver mutation in response to an EGFR neopeptide vaccine [177].